BioTuesdays
Roth
Developments

Roth Capital acquires MKM Partners

Roth Capital Partners completed its acquisition of MKM Partners on Jan. 31, and the combined organization will conduct business as ROTH MKM. This is the first acquisition ROTH has made in its 30-plus years of business...

February 1, 2023
Hepion Logo
Markets

AGP starts Hepion at buy; PT $4

Alliance Global Partners launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and price target of $4. Shares of Hepion closed at 73 cents on Jan. 31. Analyst James Molloy writes that his...

February 1, 2023
Editas-Logo
Markets

Cantor starts Editas Medicine at OW; PT $15

Cantor Fitzgerald initiated coverage of Editas Medicine (NASDAQ:EDIT) with an “overweight” rating and 12-month price target of $15. The stock closed at $9.35 on Jan. 31. Editas is a clinical-stage gene editing company...

February 1, 2023
Precigen-Logo
Markets

Cantor ups Precigen PT after R&D event

Cantor Fitzgerald raised its price target for Precigen (NASDAQ:PGEN) to $10 from $7 after the company held an R&D event to showcase safety and efficacy data from a Phase 1 trial. The stock closed at $1.64 on Jan. 27...

January 30, 2023
Celularity-Logo
Markets

HCW slashes Celularity PT on pipeline priority changes

H.C. Wainwright reduced its price target for Celularity (NASDAQ:CELU) to $2.50 from $15, but reiterated a “buy” rating, after the company unveiled a strategic shift in its pipeline. The stock closed at $1.05 on Jan. 27...

January 30, 2023
Markets

Dawson James starts Genprex at buy; PT $3

Dawson James Securities initiated coverage of Genprex (NASDAQ:GNPX) with a “buy” rating and $3 price target. The stock closed at $1.34 on Jan. 27. Genprex is a clinical-stage gene therapy company pioneering the...

January 30, 2023
Compass-Logo
Markets

Stifel starts Compass Therapeutics at buy; PT $9

Stifel initiated coverage of Compass Therapeutics (NASDAQ:CMPX) with a “buy” rating and price target of $9. The stock closed at $3.95 on Jan. 26. “We believe the recent presentation at ASCO-GI 2023 of updated results...

January 27, 2023
Elucid-Logo
Executive Moves

Elucid names Scott Burger as CCO

Elucid, a closely-held medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, appointed Scott Burger as chief commercial officer. His...

January 26, 2023